Socio-economic impact of tocilizumab (TCZ), other bDMARD and tsDMARD treatment on Japanese Rheumatoid Arthritis patients using CorEvitas' RA Japan registry
Latest Information Update: 15 Apr 2022
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 13 Apr 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 07 Jul 2021 New trial record